Based on the Evoke Pharma Inc stock forecast from 0 analysts, the average analyst target price for Evoke Pharma Inc is not available over the next 12 months. Evoke Pharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Evoke Pharma Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Evoke Pharma Inc’s stock price was USD 2.33. Evoke Pharma Inc’s stock price has changed by +5.38% over the past week, -17.41% over the past month and -58.57% over the last year.
No recent analyst target price found for Evoke Pharma Inc
No recent average analyst rating found for Evoke Pharma Inc
Company Overview Evoke Pharma Inc
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. Read Less
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and ...Read More
Frequently Asked Questions About Evoke Pharma Inc (EVOK) Stock
Stock Target Advisor's fundamental analysis for Evoke Pharma Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on EVOK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EVOK's stock to indicate what its average analyst target is.
EVOK stock's Price/Earning ratio is 0.04.
Our analysis grades EVOK stock's Price / Earning ratio at A. This means that EVOK stock's Price/Earning ratio is above 6.999999999999995% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this EVOK may be undervalued for its sector.
The last closing price of EVOK's stock was USD 2.33.
The most recent market capitalization for EVOK is USD 4.21M.
Unfortunately we do not have enough analyst data on EVOK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Evoke Pharma Inc's stock.
As per our most recent records Evoke Pharma Inc has 3 Employees.
Evoke Pharma Inc's registered address is 420 Stevens Avenue, Solana Beach, CA, United States, 92075.
You can get more information about it from Evoke Pharma Inc's website at https://www.evokepharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Evoke Pharma Inc (EVOK) Stock
Stock Target Advisor's fundamental analysis for Evoke Pharma Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on EVOK's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on EVOK's stock to indicate what its average analyst target is.
EVOK stock's Price/Earning ratio is 0.04.
Our analysis grades EVOK stock's Price / Earning ratio at A. This means that EVOK stock's Price/Earning ratio is above 6.999999999999995% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this EVOK may be undervalued for its sector.
The last closing price of EVOK's stock was USD 2.33.
The most recent market capitalization for EVOK is USD 4.21M.
Unfortunately we do not have enough analyst data on EVOK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Evoke Pharma Inc's stock.
As per our most recent records Evoke Pharma Inc has 3 Employees.
Evoke Pharma Inc's registered address is 420 Stevens Avenue, Solana Beach, CA, United States, 92075.
You can get more information about it from Evoke Pharma Inc's website at https://www.evokepharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EVOK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
